PPT-PRESENT STATUS OF PROSTATE CANCER TREATMENT AND THE ROLE OF IMAGING

CÉSAR DAVID VERADONOSO Department of Urology WHO IS IN THE LINE OF FIRE WE NEED TO COLLABORATE IN MANY FIELDS WE NEED RELIABLE IMAGES TO TAKE DECISIONS INCIDENCE EUROPE In Europe PCa. Analysis. Charles . J Ryan, MD. Professor of Clinical . Medicine and Urology. Helen Diller Family Comprehensive Cancer Center. University of California, San Francisco. Biomarker Analysis in Prostate . Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . Maurizio Conti. Siemens Healthcare Molecular Imaging, Knoxville, Tennessee, USA. Mediterranean Thematic Workshops in Advanced Molecular Imaging. Alghero. , September 2-7, 2014. index. . motivation & introduction. When to Image Based on . Choosing . Wisely. ®. . and ACR Appropriateness . Criteria. ®. What Is R-SCAN?. 2. C. ollaborative activity . for referring clinicians and radiologists to improve patient . 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, et al. JAMA . Oncol. . 2015; 1(4): 505-27/ 2. . Droz. JP, et al. Lancet . Oncol. . 2014; 15(9): e404-14/ 3. . Cuzick. J, et al. Lancet . Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, No significant relationship exists between the authors and the compa-nies/organizations whose products or services may be referenced inthis article. Abbreviations used in this paper:CT = computed tomo Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. By: Ishan Parikh. Symptoms. Be on the look out for…. “stop-and-go” flow of urine. Sudden urges to urinate. Frequent urination (esp. at nights). Trouble starting urination. Trouble with emptying bladder completely. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. NASPCC 10-13-18. Ronald Chen, MD MPH. Associate Professor, Radiation Oncology. University of North Carolina – Chapel Hill. Associate Director, UNC Lineberger Comprehensive Cancer Center. Disclosures. Session Objectives. Updates of the Status of Research Effort. Evaluation of Biomarker Development Status. Imaging and Urine Testing to Enhance Prostate Cancer Detection. Martin . Sanda. , M.D., Emory University. CVC.